Skip to main content

Innate and Adaptive Cellular Cytotoxicity Laboratory

Photo of Guido Ferrari, MD

Guido Ferrari, MD

Office: 115 Surg Oncol Res Fac, Durham, NC 27710
Campus Mail: Box 2926 Med Ctr, Durham, NC 27710
Phone: 919-684-2862

Scientific Focus

The overall goal of the laboratory is to understand the ontogeny of HIV-1 specific MHC class I-restricted and non-restricted immune responses that work by eliminating HIV-1 infected cells and how these can be induced by AIDS vaccine candidates. The studies gravitate around class I-mediated cytotoxic CD8+ T cell responses, antibody-dependent cellular cytotoxicity (ADCC), gene expression in effector cellular subsets, and development of Ab-based molecules that can engage cytotoxic effector subsets.

  • Pre-clinical evaluation of Dual-Affinity Re-Targeting molecules to eradicate HIV-1 latently infected cells.
  • Understanding differences between human and non-human primate effector functions of Fc-gamma Receptor-bearing cells.
  • Immune monitoring of Fc-mediated Ab cytotoxic responses in pre- and clinical passive and active immunization studies.

Selected Achievements

The laboratory team has worked since 2001 on testing samples from vaccine recipients for cytotoxic T lymphocyte (CTL) and antibody-dependent cellular cytotoxic (ADCC) responses as part of the AIDS Vaccine Evaluating Group (AVEG) and, subsequently, for the HIV vaccine trial network (HVTN). The laboratory team was the first to characterize vaccine-induced cross-clade clade CD8 CTL responses and the difference in class I-restricted epitope recognition between HIV-1 infected individuals and vaccine recipients. The laboratory team followed up this initial epitope mapping of cellular responses with the epitope mapping of ADCC responses.

In 2011, the team reported the anti-C1 epitope as the most recognized epitope by ADCC ab responses in infected individuals. The laboratory has gained a unique expertise in exploring the breadth and mapping of HIV-1 epitopes recognized by the cellular and humoral responses of the immune system. Its expertise has provided essential in designing the novel class of therapeutics named DARTs in collaboration with our colleagues at UNC-Chapel Hill and MacroGenics.

Contact Us

For pre- and clinical trial studies: Dr. Guido Ferrari or Mrs. Sherry Stanfield-Oakely:

For basic science studies: Dr. Justin Pollara:

For flow cytometry questions: Mrs. Joy A Pickeral,

For ELISPOT questions: Mr. Mark Berrong,

For administrative questions: Mrs. Mary Oris , or Mrs. Melissa Kerkau,

Latest Publications

Chua, Joel V., Charles Davis, Jennifer S. Husson, Amy Nelson, Ilia Prado, Robin Flinko, Ka Wing J. Lam, et al. “Safety and immunogenicity of an HIV-1 gp120-CD4 chimeric subunit vaccine in a phase 1a randomized controlled trial.” Vaccine 39, no. 29 (June 29, 2021): 3879–91.

Full Text

Saunders, Kevin O., Norbert Pardi, Robert Parks, Sampa Santra, Zekun Mu, Laura Sutherland, Richard Scearce, et al. “Lipid nanoparticle encapsulated nucleoside-modified mRNA vaccines elicit polyfunctional HIV-1 antibodies comparable to proteins in nonhuman primates.” Npj Vaccines 6, no. 1 (April 9, 2021): 50.

Full Text

Tolbert, William D., Verna Van, Rebekah Sherburn, Marina Tuyishime, Fang Yan, Dung N. Nguyen, Sherry Stanfield-Oakley, et al. “Erratum for Tolbert et al., "Recognition Patterns of the C1/C2 Epitopes Involved in Fc-Mediated Response in HIV-1 Natural Infection and the RV114 Vaccine Trial".” Mbio 12, no. 2 (April 6, 2021).

Full Text

Andersen-Nissen, Erica, Andrew Fiore-Gartland, Lamar Ballweber Fleming, Lindsay N. Carpp, Anneta F. Naidoo, Michael S. Harper, Valentin Voillet, et al. “Innate immune signatures to a partially-efficacious HIV vaccine predict correlates of HIV-1 infection risk.” Plos Pathog 17, no. 3 (March 2021): e1009363.

Full Text